Logo image of PYXS

PYXIS ONCOLOGY INC (PYXS) Stock Fundamental Analysis

NASDAQ:PYXS - Nasdaq - US7473241013 - Common Stock - Currency: USD

1.28  -0.08 (-5.88%)

After market: 1.2882 +0.01 (+0.64%)

Fundamental Rating

2

Overall PYXS gets a fundamental rating of 2 out of 10. We evaluated PYXS against 571 industry peers in the Biotechnology industry. PYXS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PYXS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year PYXS has reported negative net income.
PYXS had a negative operating cash flow in the past year.
PYXS had negative earnings in each of the past 5 years.
In the past 5 years PYXS always reported negative operating cash flow.
PYXS Yearly Net Income VS EBIT VS OCF VS FCFPYXS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

With a decent Return On Assets value of -29.37%, PYXS is doing good in the industry, outperforming 69.63% of the companies in the same industry.
Looking at the Return On Equity, with a value of -37.32%, PYXS is in the better half of the industry, outperforming 73.18% of the companies in the same industry.
Industry RankSector Rank
ROA -29.37%
ROE -37.32%
ROIC N/A
ROA(3y)-42.24%
ROA(5y)-53.3%
ROE(3y)-54.28%
ROE(5y)-76.2%
ROIC(3y)N/A
ROIC(5y)N/A
PYXS Yearly ROA, ROE, ROICPYXS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -50 -100 -150 -200

1.3 Margins

PYXS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PYXS Yearly Profit, Operating, Gross MarginsPYXS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

4

2. Health

2.1 Basic Checks

Compared to 1 year ago, PYXS has more shares outstanding
PYXS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PYXS Yearly Shares OutstandingPYXS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M 40M
PYXS Yearly Total Debt VS Total AssetsPYXS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

PYXS has an Altman-Z score of -1.52. This is a bad value and indicates that PYXS is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.52, PYXS is in line with its industry, outperforming 55.24% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that PYXS is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.00, PYXS perfoms like the industry average, outperforming 48.13% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.52
ROIC/WACCN/A
WACCN/A
PYXS Yearly LT Debt VS Equity VS FCFPYXS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 100M 200M

2.3 Liquidity

PYXS has a Current Ratio of 7.33. This indicates that PYXS is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of PYXS (7.33) is better than 69.09% of its industry peers.
A Quick Ratio of 7.33 indicates that PYXS has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 7.33, PYXS is in the better half of the industry, outperforming 69.27% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.33
Quick Ratio 7.33
PYXS Yearly Current Assets VS Current LiabilitesPYXS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 59.29% over the past year.
EPS 1Y (TTM)59.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 3.42% on average over the next years.
Based on estimates for the next years, PYXS will show a very strong growth in Revenue. The Revenue will grow by 158.26% on average per year.
EPS Next Y39.82%
EPS Next 2Y13.07%
EPS Next 3Y9.6%
EPS Next 5Y3.42%
Revenue Next Year8187.48%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y158.26%

3.3 Evolution

PYXS Yearly Revenue VS EstimatesPYXS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
PYXS Yearly EPS VS EstimatesPYXS Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PYXS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PYXS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PYXS Price Earnings VS Forward Price EarningsPYXS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PYXS Per share dataPYXS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.07%
EPS Next 3Y9.6%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PYXS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PYXIS ONCOLOGY INC

NASDAQ:PYXS (2/21/2025, 8:00:01 PM)

After market: 1.2882 +0.01 (+0.64%)

1.28

-0.08 (-5.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)03-20 2025-03-20/amc
Inst Owners41.24%
Inst Owner Change-93.79%
Ins Owners7.68%
Ins Owner Change0%
Market Cap76.12M
Analysts85.71
Price Target9.03 (605.47%)
Short Float %15.79%
Short Ratio8.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.41%
Min EPS beat(2)-9.51%
Max EPS beat(2)12.33%
EPS beat(4)3
Avg EPS beat(4)27.6%
Min EPS beat(4)-9.51%
Max EPS beat(4)75.69%
EPS beat(8)5
Avg EPS beat(8)21.67%
EPS beat(12)5
Avg EPS beat(12)-26.52%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-10.14%
PT rev (3m)-3.38%
EPS NQ rev (1m)-1.76%
EPS NQ rev (3m)-23.36%
EPS NY rev (1m)-0.39%
EPS NY rev (3m)-7.35%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.96%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.71
P/FCF N/A
P/OCF N/A
P/B 0.5
P/tB 0.59
EV/EBITDA N/A
EPS(TTM)-1.03
EYN/A
EPS(NY)-1.33
Fwd EYN/A
FCF(TTM)-0.91
FCFYN/A
OCF(TTM)-0.9
OCFYN/A
SpS0.27
BVpS2.58
TBVpS2.19
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.37%
ROE -37.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.24%
ROA(5y)-53.3%
ROE(3y)-54.28%
ROE(5y)-76.2%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.47%
Cap/Sales 1.44%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.33
Quick Ratio 7.33
Altman-Z -1.52
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)444.51%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)59.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.5%
EPS Next Y39.82%
EPS Next 2Y13.07%
EPS Next 3Y9.6%
EPS Next 5Y3.42%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year8187.48%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y158.26%
EBIT growth 1Y34.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-65.18%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y39.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.24%
OCF growth 3YN/A
OCF growth 5YN/A